Analysts See $-0.25 EPS for Spectrum Pharmaceuticals, Inc. (SPPI)

February 15, 2018 - By Dolores Ford

 Analysts See $ 0.25 EPS for Spectrum Pharmaceuticals, Inc. (SPPI)
Investors sentiment increased to 2.84 in 2017 Q3. Its up 1.89, from 0.95 in 2017Q2. It is positive, as 13 investors sold Spectrum Pharmaceuticals, Inc. shares while 19 reduced holdings. 38 funds opened positions while 53 raised stakes. 71.60 million shares or 29.39% more from 55.33 million shares in 2017Q2 were reported.
Pub Employees Retirement Association Of Colorado has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Envestnet Asset Management Inc stated it has 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Kennedy Mngmt Inc has 0.13% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 515,419 shares. 64,690 are held by Granite Investment Prns Limited Company. Tci Wealth Advisors Inc holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 247 shares. Bogle Invest Management L P De owns 231,132 shares. 16,566 were accumulated by Piedmont Investment Advsr Ltd. Fifth Third National Bank has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 1,010 shares. Vantage Invest Advisors Lc owns 200 shares for 0% of their portfolio. Ameriprise Finance reported 396,331 shares stake. Goldman Sachs Group Inc owns 1.81M shares. Morgan Stanley has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Great West Life Assurance Can has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). M&T Natl Bank Corporation has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Jpmorgan Chase And owns 52,741 shares.

Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.25 EPS on March, 14.They anticipate $0.03 EPS change or 13.64 % from last quarter’s $-0.22 EPS. After having $-0.22 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see 13.64 % EPS growth. The stock increased 1.55% or $0.33 during the last trading session, reaching $21.61. About 405,645 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 20.03% since February 15, 2017 and is downtrending. It has underperformed by 36.73% the S&P500.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma had 11 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, June 7, the company rating was maintained by Jefferies. The company was maintained on Friday, February 10 by Jefferies. The rating was maintained by Jefferies on Monday, October 9 with “Buy”. The stock has “Hold” rating by Zacks on Thursday, August 27. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) earned “Buy” rating by Jefferies on Thursday, August 24. On Wednesday, August 16 the stock rating was reinitiated by H.C. Wainwright with “Buy”. As per Thursday, November 5, the company rating was maintained by RBC Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Friday, August 7.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $2.15 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

More notable recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: which released: “Spectrum Pharmaceuticals to Present Corporate Update at the Noble Capital …” on January 23, 2018, also with their article: “Spectrum Pharmaceuticals Up 134% in 6 Months: Here’s Why” published on January 19, 2018, published: “Spectrum Pharmaceuticals: What Does The Recent Management Streamlining Signify?” on February 07, 2018. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) were released by: and their article: “Spectrum Pharmaceuticals: What The Positive ADVANCE Study Entails?” published on February 07, 2018 as well as‘s news article titled: “Spectrum Pharma’s Rolontis Positive in Pivotal Cancer Study” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.